From Wikipedia, the free encyclopedia

TypePrivately held company
Industryresearch and development in biotechnology Edit this on Wikidata
FoundedMarseille, France (1999 (1999))
  • Christopher Henderson
  • Olivier Pourquie
  • Jean-Louis Kraus
  • Antoine Beret
  • Michel Delaage
Defunct2015 (2015)
FateAcquired by Hoffmann-La Roche
France Edit this on Wikidata

Trophos was a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.[citation needed]

Trophos was founded in 1999 in Marseille by three scientists: Christopher Henderson, Olivier Pourquie and Jean-Louis Kraus, and two entrepreneurs: Antoine Beret and Michel Delaage. Trophos' lead compound was olesoxime (TRO19622),[1][2] a mitochondrial targeted compound developed to treat neurodegenerative diseases.[3][4]

In January 2015, Hoffmann-La Roche announced its intention to buy Trophos for 120,000,000 upfront and up to 350,000,000 in milestone performance payments.[5][6] The deal was completed shortly afterwards.


  1. ^ Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N. P.; Evers, A. S.; Covey, D. F.; Ostuni, M. A.; Lacapere, J.-J.; Massaad, C.; Schumacher, M.; Steidl, E.-M.; Maux, D.; Delaage, M.; Henderson, C. E.; Pruss, R. M. (2007). "Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis". Journal of Pharmacology and Experimental Therapeutics. 322 (2): 709–720. doi:10.1124/jpet.107.123000. PMID 17496168. S2CID 17271734.
  2. ^ "olesoxime". UKMi New Drugs Online Database. Retrieved 2 January 2016.
  3. ^ "Effect of TRO19622 in the Treatment of Patients With Chemotherapy Induced Peripheral Neuropathy". 5 February 2010. Retrieved 3 October 2010.
  4. ^ "Safety and Efficacy of TRO19622 as add-on Therapy to Riluzole Versus Placebo in Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)". May 2010. Retrieved 3 October 2010.
  5. ^ Franklin, Joshua (16 January 2015). "Roche buys France's Trophos to expand in neuromuscular disease". Reuters. Retrieved 30 December 2015.
  6. ^ Staff (15 February 2015). "Roche to Buy Trophos for Up-to-$543M". Genetic Engineering & Biotechnology News (paper). Vol. 35, no. 4. p. 6.

Further reading[edit]